Experimental treatment pushed by ALS patients gets day...
The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease
Stay updated with breaking news from Anthony Windebank. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease
The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.
In documents posted Monday, the FDA reiterated its longstanding position that drugmaker Brainstorm's lone study doesn't provide convincing evidence that its stem cell-based therapy helps patients with ALS, or amyotrophic lateral sclerosis.
The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.
The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.